Dosage regimen of MDM2 inhibitor for treating cancers
Patent Information
- Application Number
- JP2024139510
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2015-10-23
- Filing Date
- 2024-08-21
- Publication Date
- 2024-11-26
- Estimated Expiration
- Not applicable · inactive patent
Smart Images

Figure 2024164122000014 
Figure 2024164122000015 
Figure 2024164122000001
Abstract
Description
[Technical field]
[0001] The present invention provides a method of treating cancer in a subject in need thereof, comprising administering and administering to a subject a specific MDM2 inhibitor according to the dosing regimen. The present invention relates to a pharmaceutical composition for use in treating cancer by using the same. A method of treating a subject in need thereof, comprising administering to the subject a specific MDM2 inhibitor. and a method for treating liposarcoma comprising administering to said patient an MDM2 inhibitor. It also relates to pharmaceutical compositions. [Background technology]
[0002] MDM2 is located on chromosome 12q13-15 and binds the p53 tumor suppressor protein. The 90 kDa MDM2 protein is a negative regulator of p53. domain and its C-terminus, which functions as an E3 ligase that ubiquitinates p53. RING (really interesting new gene) domain Activation of wild-type p53 by cell stimulation and stress is mediated by the N-terminal transcription factor MDM2. It binds to p53, inhibits p53 transcriptional activation, and mediates the ubiquitin-proteasome Thus, MDM2 inhibits p53-mediated apoptosis. It prevents the arrest of cytokinesis and cancer cell proliferation, and important oncogenic activities in cancer cells are attributed to MDM2. In some cases, MDM2 may be involved in the transcription of IL-1, e.g., alternative splices of MDM2. In cells with the p53-dependent phenotype, it may cause oncogenesis independent of the p53 pathway (H A. Steinman et al., 2004, J. Biol. Chem., 279(6):48 77-4886). Therefore, several MDM2 inhibitors have been developed to treat cancer. This includes (3'R,4'S,5'R)-N-[(3R,6S)-6-carbamoyl tetrahydrofuran tetrahydro-2H-pyran-3-yl]-6”-chloro-4'-(2-chloro-3-fluoro (4,4-dimethyl-2”-oxo-1”,2”-dihydropyridin-4-yl)- Spiro[cyclohexane-1,2'-pyrrolidine-3',3”-indole]-5'-catechin Ruboxamide (WO 2012 / 121361 and U.S. Patent Application Publication No. 2012 / 026 4738A).
[0003] Liposarcoma (LPS) is the most common subtype of soft tissue sarcoma (STS) in humans. LPS is one of the types of STS that comprises approximately 18 to 26% of STS cases. l-differentiated) type (WD, 46 to 54%), dedifferentiated type (DD, 18 to 26%), myxoid / round cell type (13 to 28%) and pleomorphic type It can be classified into four subtypes: Amplification of gene 5 is frequently found in WD / DD LPS (i.e., in up to about 90% of patients). (Coindre et al., 2010, Virchows. Arch. 456:167 -179, Momand et al., 1998, Nucleic Acid Research, 26(15):3453-3459, and Rayburn et al., 2005, Curren t Cancer Drug Targets, 5:27-41). MDM2 antagonists have been developed as treatments for liposarcoma (Ray-Coquartz d et al., 2012, Lancet Oncol., 13:1133-1140). Summary of the Invention
[0004] The present invention involves administering a particular MDM2 inhibitor to a subject according to a particular dosing regimen. and a method for treating cancer in a subject in need thereof according to said administration regimen. The present invention provides a pharmaceutical composition for use in treating a subject with a specific MDM2 inhibitor. and a method for treating liposarcoma in a subject in need thereof, comprising administering an anti-inflammatory agent to the subject. Also provided is a pharmaceutical composition for use in treating liposarcoma comprising an MDM2 inhibitor.
[0005] Solid tumors and lymphomas were treated with a daily dose of 80 to 250 mg of the compound or its salt. Dosing regimens involving cyclic dosing (QD21 / 28 or QD28 / 28) in elephants According to (3'R,4'S,5'R)-N-[(3R,6S)-6-Carbamoyltetrahydro- 2H-pyran-3-yl]-6”-chloro-4'-(2-chloro-3-fluoropyridine -4-yl)-4,4-dimethyl-2”-oxo-1”,2”-dihydrodispiro[cyclo Hexane-1,2'-pyrrolidine-3',3”-indole]-5'-carboxamide (hereinafter also referred to as "Compound 1") or a pharma- ceutical acceptable salt thereof is orally administered to a subject. The inventors have discovered that liposarcoma can be treated by administering Compound 1. The inventors have also discovered that it is possible to treat
[0006] The present invention provides the following: (1) A therapeutically effective amount of a compound of formula (I) or a pharma- ceutical acceptable salt thereof. 1. A pharmaceutical composition for use in treating cancer in a subject, comprising about 80 mg of 2. The method of claim 1, further comprising administering to a subject a daily dose of about 250 mg to about 250 mg of the compound or a salt thereof. A pharmaceutical composition administered orally on a schedule. [ka] (3'R,4'S,5'R)-N-[(3R,6S)-6-Carbamoyltetrahydro- 2H-pyran-3-yl]-6”-chloro-4'-(2-chloro-3-fluoropyridine -4-yl)-4,4-dimethyl-2”-oxo-1”,2”-dihydrodispiro[cyclo Hexane-1,2'-pyrrolidine-3',3”-indole]-5'-carboxamide (2) a dosing schedule comprising a daily dose of about 80 mg to about 140 mg of the compound or The pharmaceutical composition according to (1) above, comprising administering the salt to a subject. (3) a dosing schedule comprising a daily dose of about 80 mg to about 100 mg of the compound or The pharmaceutical composition according to (1) above, comprising administering the salt to a subject. (4) The dosing schedule provides for a daily dose of about 90 mg of the compound or a salt thereof to be administered to the subject. The pharmaceutical composition according to (1) above, (5) The dosing schedule comprises a daily dose of about 100 mg to about 140 mg of the compound or The pharmaceutical composition according to (1) above, comprising administering to a subject a salt of the formula: (6) The dosing schedule is such that a daily dose of about 120 mg of the compound or a salt thereof is administered to the subject. The pharmaceutical composition according to (1) above, (7) The method according to any one of (1) to (6) above, wherein the cancer is liposarcoma. A pharmaceutical composition for use in treating cancer in a subject in need thereof. (8) the cancer is a liposarcoma with an amplified MDM2 gene in the liposarcoma genome; or (7) above for use in treating cancer in a subject in need thereof. A pharmaceutical composition of. (9) A therapeutically effective amount of a compound of formula (I) or a pharma- ceutical acceptable salt thereof. A pharmaceutical composition for use in treating cancer in a subject in need thereof, comprising: The drug is administered orally for at least one cycle of the dosing schedule, each cycle comprising at least and a dosing period of at least 10 days, and the compound or salt thereof is administered in a dose of about 80 mg to about 250 mg. A pharmaceutical composition administered daily in a daily dosage. (10) The compound or a salt thereof is administered daily in a daily dosage of about 80 mg to about 140 mg. The pharmaceutical composition according to (9) above. (11) The compound or a salt thereof is administered daily in a daily dosage of about 80 mg to about 100 mg. The pharmaceutical composition according to (9) above. (12) The compound or a salt thereof according to (9), wherein the compound or a salt thereof is administered daily in a daily dosage of about 90 mg. The pharmaceutical composition described in (13) The compound or a salt thereof is administered daily in a daily dosage of about 100 mg to about 140 mg. The pharmaceutical composition according to (9) above. (14) The method according to any one of the above (9), wherein the compound or a salt thereof is administered daily in a daily dosage of about 120 mg. ) The pharmaceutical composition described in (15) The compound or a salt thereof is administered daily in a daily dosage of about 140 mg to about 180 mg. The pharmaceutical composition according to (9) above. (16) The method according to any one of the above (9), wherein the compound or a salt thereof is administered daily in a daily dosage of about 160 mg. ) The pharmaceutical composition described in (17) The compound or a salt thereof is administered daily in a daily dosage of about 180 mg to about 250 mg. The pharmaceutical composition according to (9) above. (18) The method according to any one of the above (9), wherein the compound or a salt thereof is administered daily in a daily dosage of about 210 mg. ) The pharmaceutical composition described in (19) A therapeutically effective amount of a compound of formula (I) or a pharma- ceutical acceptable salt thereof. A pharmaceutical composition for use in treating cancer in a subject in need thereof, comprising: The drug is administered orally for at least one cycle of the dosing schedule, each cycle comprising about 1 The dosing period is from 5 to about 25 days, and the compound or salt thereof is administered in an amount of about 8 to about 100 mg / kg of the compound or salt thereof. is administered daily in a daily dosage of 0 mg to about 250 mg, followed by about 5 to about 10 days of rest. The pharmaceutical composition wherein neither the compound nor its salts are administered during the drug administration period. [ka] (3'R,4'S,5'R)-N-[(3R,6S)-6-Carbamoyltetrahydro- 2H-pyran-3-yl]-6”-chloro-4'-(2-chloro-3-fluoropyridine -4-yl)-4,4-dimethyl-2”-oxo-1”,2”-dihydrodispiro[cyclo Hexane-1,2'-pyrrolidine-3',3”-indole]-5'-carboxamide (20) Each cycle has a dosing period of about 15 to about 25 days, and the compound or salt thereof , administered daily at a daily dosage of about 100 mg to about 140 mg, followed by about 5 days to about 1 During the washout period of day 0, neither the compound nor its salt is administered. 19) A pharmaceutical composition according to any one of the above. (21) Each cycle has a dosing period of about 15 to about 25 days, and the compound or salt thereof , administered daily at a daily dosage of about 120 mg, followed by a drug-free period of about 5 to about 10 days. any of the above (9) to (19), in which neither the compound nor a salt thereof is administered 1. A pharmaceutical composition as described in Item 1. (22) Each cycle has a dosing period of about 15 to about 25 days, and the compound or salt thereof , administered daily at a daily dosage of about 140 mg to about 180 mg, followed by about 5 days to about 1 During the washout period of day 0, neither the compound nor its salt is administered. 19) A pharmaceutical composition according to any one of the above. (23) each cycle has a dosing period of about 15 to about 25 days, and the compound or salt thereof , administered daily at a daily dosage of about 160 mg, followed by a drug-free period of about 5 to about 10 days. any of the above (9) to (19), in which neither the compound nor a salt thereof is administered 1. A pharmaceutical composition as described in Item 1. (24) Each cycle has a dosing period of about 15 to about 25 days, and the compound or salt thereof , administered daily at a daily dosage of about 180 mg to about 250 mg, followed by about 5 days to about 1 During the washout period of day 0, neither the compound nor its salt is administered. 19) A pharmaceutical composition according to any one of the above. (25) Each cycle has a dosing period of about 15 to about 25 days, and the compound or salt thereof , administered daily at a daily dosage of about 210 mg, followed by a drug-free period of about 5 to about 10 days. any of the above (9) to (19), in which neither the compound nor a salt thereof is administered 1. A pharmaceutical composition as described in Item 1. (26) Each cycle has a dosing period of about 21 days, and the compound or a salt thereof is administered for about 100 minutes. The compound is administered daily at a daily dosage of about 100 mg to about 140 mg, followed by a rest period of about 7 days. The method according to any one of (9) to (19) above, in which neither the compound nor its salt is administered. The pharmaceutical composition described above. (27) Each cycle has a dosing period of about 21 days, and the compound or a salt thereof is administered for about 140 minutes. The compound is administered daily at a daily dosage of about 180 mg to about 180 mg, followed by a rest period of about 7 days. The method according to any one of (9) to (19) above, in which neither the compound nor its salt is administered. The pharmaceutical composition described above. (28) Each cycle has a dosing period of about 21 days, and the compound or a salt thereof is administered for about 180 minutes. The compound is administered daily at a daily dosage of about 250 mg to about 250 mg, followed by a rest period of about 7 days. The method according to any one of (9) to (19) above, in which neither the compound nor its salt is administered. The pharmaceutical composition described above. (29) Each cycle has a dosing period of about 15 to about 25 days, and the compound or salt thereof , administered daily at a daily dosage of about 80 mg to about 100 mg, followed by about 5 to about 10 During the drug holiday period, neither the compound nor its salt is administered. 9) A pharmaceutical composition according to any one of the above. (30) Each cycle has a dosing period of about 15 to about 25 days, and the compound or salt thereof , administered daily at a daily dosage of about 90 mg, followed by a drug holiday of about 5 to about 10 days. and any one of the above (9) to (19), in which the compound and its salt are not administered. The pharmaceutical composition described above. (31) Each cycle has a dosing period of about 21 days, and the compound or a salt thereof is administered in a dose of about 80 mg. to about 100 mg daily, followed by a rest period of about 7 days, The method according to any one of (9) to (19) above, wherein neither the compound nor its salt is administered. A pharmaceutical composition comprising: (32) Each cycle has a dosing period of about 21 days, and the compound or a salt thereof is is administered daily at a daily dosage of about 120 mg of its salt, followed by a drug holiday of about 7 days. Any one of the above (9) to (19), in which neither the compound nor its salt is administered. The pharmaceutical composition described in (33) Each cycle has a dosing period of about 21 days, and the compound or a salt thereof is is administered daily at a daily dosage of about 160 mg of its salt, followed by a drug holiday of about 7 days. Any one of the above (9) to (19), in which neither the compound nor its salt is administered. The pharmaceutical composition described in (34) Each cycle has a dosing period of about 21 days, and the compound or a salt thereof is is administered daily at a daily dosage of about 210 mg of its salt, followed by a drug holiday of about 7 days. Any one of the above (9) to (19), in which neither the compound nor its salt is administered. The pharmaceutical composition described in (35) Each cycle has a dosing period of about 21 days, and the compound or a salt thereof is is administered daily at a daily dosage of about 90 mg of the salt, followed by a drug holiday of about 7 days. The compound and its salt are not administered to any one of the above (9) to (19). The pharmaceutical composition described. (36) The method according to any one of (9) to (35) above, wherein the cancer is liposarcoma. A pharmaceutical composition for use in treating cancer in a subject in need thereof. (37) The cancer is a liposarcoma with an amplified MDM2 gene in the liposarcoma genome. The method according to (36) above for treating cancer in a subject in need thereof. A pharmaceutical composition for use in treating (38) The compound or a salt thereof is represented by the formula (II): p-toluenesulfonate monohydrate Any of the above (1) to (37) in the form of a solvate (hereinafter also referred to as "compound 2"). 1. A pharmaceutical composition for use in treating cancer in a subject in need thereof, comprising: composition. [ka] (39) (3'R,4'S,5'R)-N-[(3R,6S)-6-Carbamoyl 6”-chloro-4’-(2-chloro-3-fluoro-4H-pyran-3-yl)- (4,4-dimethyl-2”-oxo-1”,2”-dihydrodisil Pyrro[cyclohexane-1,2'-pyrrolidine-3',3”-indole]-5'-carbazolyl A compound comprising voxamide or a pharma- ceutical acceptable salt thereof for use in treating liposarcoma. A pharmaceutical composition for the treatment of (40) The liposarcoma has an amplified MDM2 gene in the liposarcoma genome, 39) A pharmaceutical composition according to the present invention. [Brief description of the drawings]
[0007] [Figure 1] Figure 1 shows a waterfall plot showing the best tumor response in all evaluable subjects (n=23) in the clinical study. Subjects with liposarcoma are indicated by the letter "L" on the bar. Baseline was defined as the last non-missing value taken before the first dose of Compound 2. For each subject, the best (smallest) percent change from baseline in the sum of diameters for all target lesions is represented by a vertical bar. The terms "PD" and "SD" mean progressive disease and stable disease, respectively, as defined by RECIST guidelines v1.1.
[0008] [Diagram 2]Figure 1 shows a waterfall plot showing the best tumor response in all subjects (n=13) with liposarcoma in a clinical study. Subjects with WD and DD liposarcoma are indicated by the letters "WD" and "DD" on the bars, respectively. Baseline was defined as the last non-missing value taken before the first dose of Compound 2. For each subject, the best (smallest) percent change from baseline in the sum of diameters for all target lesions is represented by a vertical bar. The terms "PD" and "SD" mean progressive disease and stable disease, respectively, as defined by RECIST guidelines v1.1. Detailed Description of the Invention
[0009] As used herein, the term "including" is intended to be open-ended and inclusive. It is intended that the closed terms "consisting of" and "comprise" do not exclude additional unstated features. includes "consisting essentially of".
[0010] The term "subject" refers to a mammal suffering from or suspected of suffering from cancer. The subject may be a patient who has been previously treated or is currently being treated with other therapies. The subject may be an adult human.
[0011] The term "treat" refers to the treatment of patients with solid tumors (RECIST) version 1.1 This will be determined by the physician according to the Response Evaluation in It refers to being able to reduce the severity of the disease or slow the progression of the disease.
[0012] The term "MDM2" refers to a molecule that can interact with p53 and cause its degradation. As used herein, "MDM2" refers to mouse MDM2, an E3 ubiquitin ligase that can Human orthologues of DM2 and MDM2 (Human Double Minute These include, but are not limited to, MDM2 inhibitors (also referred to as "MDM2" or "HDM2"). The term “inhibitor” refers to an inhibitor that inhibits MDM2 function or activity in the degradation of p53. represent.
[0013] The term "binding" refers to the hybridization of one nucleic acid molecule to another (or to itself). association of a polypeptide, protein, or peptide with an antibody; or Between two substances or molecules, such as the association of a protein with another protein or nucleic acid molecule The term generally refers to an interaction or association between two oligonucleotides, each of which is a single unit of an oligonucleotide. A nucleotide molecule is base paired or hybridized with its target nucleic acid molecule. When present, the oligonucleotide molecule binds or is stably associated with the target nucleic acid molecule. Preferentially, binding occurs when one molecule binds with high affinity to another molecule and with low affinity to a heterologous molecule. Binding refers to an association that affects the physical or functional properties of the target / oligonucleotide complex. Binding can be detected by any procedure known to those of skill in the art, such as by measuring the binding of Observable effects on processes such as gene expression, DNA replication, transcription, translation, etc. The protein can be functionally detected by determining whether
[0014] As used herein, the term "gene" refers to a gene that is expressed in a subject as an RNA transcript. represents a DNA sequence; gene refers to a full-length gene (a gene that encodes a protein or encoding).
[0015] "Gene expression" as used in the context of the present invention refers to the transfer of genetic information encoded by a gene to a living organism. The transcription of the offspring (e.g., mediated by the enzymatic action of RNA polymerase) into RNA (e.g., mRNA, rRNA, tRNA, or snRNA) that encodes a protein For genes that produce proteins, the process of converting the mRNA into proteins through "translation" is referred to as Taste.
[0016] As used herein, the term "cancer" refers to a tumor that, if left untreated, spreads to surrounding tissue. Invade and spread to other organs, i.e., abnormal growths or abnormal growths that can become malignant It is understood that the term encompasses neoplasms and tumors, which refer to cells that are An abnormal growth (or mass) of tissue composed of cells that form in a way that can be benign or malignant. Neoplasms and tumors are abnormal growth and proliferation of cells. This can include abnormal growth of tissue that, if untreated, grows more rapidly than normal cells. These cells continue to grow and compete with normal cells for nutrients. In addition, blood cell neoplasia or neoplasms These may include solid and non-solid tumors, such as lymphomas, leukemias, and myelomas.
[0017] The term "cancer" refers to a variety of origins, types and subtypes in or on the body. types, as well as organ, tissue and cell samples and specimens, e.g., biological samples or specimens thereof The term "cancer" is also intended to encompass neoplasms and tumors of the specimen. Exemplarily, suitable cancer samples include Alternatively, the specimen may be a human, e.g., a patient undergoing treatment for cancer, or a veterinary subject. The sample may be any conventional biological sample or specimen, including a clinical sample obtained from It may represent a portion of a tissue, a diseased or healthy part of the tissue, or the whole tissue. can be prepared by using any method or procedure known and practiced in the art. can be obtained from the subject.
[0018] The term "liposarcoma" refers to a type of tumor in adults that resembles fat cells in tissue sections under a microscope. Liposarcoma accounts for approximately 18 to 26 percent of soft tissue sarcomas. According to the pathological study, liposarcoma is classified as well-differentiated (WD, 46 to 54%). ), dedifferentiated (DD, 18 to 26%), myxoid / round cell (13 to 28%), and Pleomorphic (7 to 8%) liposarcoma can be divided into four subtypes: Chromosome 12 q13-15 amplification is a common marker for liposarcoma in subjects with liposarcoma, e.g., WD or DD liposarcoma. The MDM2 gene is known to be located on chromosome 12q13-15. It is known that the MDM2 gene is frequently amplified in subjects with liposarcoma. It is estimated that this will be the case.
[0019] The term "pharmaceutically acceptable salt" refers to a relatively non-toxic acid or base addition salt of an active compound. Non-limiting examples of acid addition salts include hydrochlorides, hydrobromides, nitrates, carbonates, etc. , phosphate, acetate, propionate, isobutyrate, maleate, malonate, benzoate Salts, succinates, fumarates, lactates, benzenesulfonates, p-toluenesulfonates "Pharmaceutically acceptable salts include acetaldehyde, citrate, tartrate, oxalate, and methanesulfonate. The term "pharmaceutically acceptable salts" includes pharmaceutically acceptable solvates or salts thereof. is a stoichiometric complex of one molecule with one or more solvent molecules. Non-limiting examples of solvates include those containing water, methanol, ethanol, dimethylsulfate, etc. as solvents. Solvates that contain water as the solvent are hydrates. In a preferred embodiment of the present invention, the pharma- ceutically acceptable salts of the compounds include hydrates and and more preferably, it may be a monohydrate.
[0020] As used herein, the term "about" refers to the particular value that follows the term and to the Expresses a range of values of ±10%. For example, the phrase "about 100" is not particularly relevant in this case. The values are 100, which is a fixed value, and the range from 90 to 110.
[0021] Compounds of formula (I): (3'R,4'S,5'R)-N-[(3R,6S)-6-Carbamoyltetrahydro- 2H-pyran-3-yl]-6”-chloro-4'-(2-chloro-3-fluoropyridine -4-yl)-4,4-dimethyl-2”-oxo-1”,2”-dihydrodispiro[cyclo Hexane-1,2'-pyrrolidine-3',3”-indole]-5'-carboxamide and its pharma- ceutically acceptable salts, including its p-toluenesulfonic acid salt, are and 5,313,636, which are incorporated herein by reference in their entireties as inhibitors of Example 70 of WO2012 / 121361 and U.S. Patent Application Publication No. 2012 / 02 (See Example 70 of US Pat. No. 64738A). [ka] Unless otherwise stated, the compounds of formula (I) include the compounds as well as their pharma- ceutically acceptable salts. By "compounds" is meant salts and pharma- ceutically acceptable solvates, and prodrugs thereof.
[0022] In one of the most preferred embodiments of the present invention, the compound is a compound of formula (II) could be: (3'R,4'S,5'R)-N-[(3R,6S)-6-Carbamoyltetrahydro- 2H-pyran-3-yl]-6”-chloro-4'-(2-chloro-3-fluoropyridine -4-yl)-4,4-dimethyl-2”-oxo-1”,2”-dihydrodispiro[cyclo Hexane-1,2'-pyrrolidine-3',3”-indole]-5'-carboxamide Mono(4-methylbenzenesulfonate) monohydrate (mono-p-toluenesulfonate of the compound) (also called sulfonate monohydrate). [ka]
[0023] Compounds of formula (I) may be administered in accordance with the dosing schedules of the present invention to treat cancer in a subject. It can therefore be administered once a day to subjects suffering from cancer.
[0024] In a preferred embodiment of the present invention, the compound of formula (I) is administered in an amount of from about 80 mg of the compound to about 2 mg of the compound. A daily dose of 50 mg may be orally administered to a subject. In certain embodiments of the present invention The compound of formula (I) is administered in an amount of about 80 mg, about 90 mg, about 100 mg, about 110 mg, about 1 20mg, about 130mg, about 140mg, about 150mg, about 160mg, about 170mg, Approx. 180mg, approx. 190mg, approx. 200mg, approx. 210mg, approx. 220mg, approx. 230m The compound can be orally administered to a subject at a daily dose of about 240 mg, about 240 mg, or about 250 mg.
[0025] In a preferred embodiment of the present invention, the compound of formula (I) is administered in an amount of from about 80 mg of the compound to about 1 40 mg, more preferably about 80 mg to about 100 mg, and even more preferably about 90 mg g daily for at least 1 week, 2 weeks, 3 weeks, 4 weeks, or more It is possible.
[0026] In a preferred embodiment of the invention, the compound of formula (I) is administered in an amount of from about 100 mg of compound to about A daily dose of 140 mg, more preferably about 120 mg, for at least 1 week, 2 weeks, 3 weeks, In another preferred embodiment of the present invention, the compound can be orally administered to a subject for a period of one week, four weeks or more. In the present invention, the compound of formula (I) is administered in an amount of about 140 mg to about 180 mg of the compound, more preferably about Subjects were given 160 mg orally daily for at least 1, 2, 3, or 4 weeks. In another preferred embodiment of the present invention, the compound of formula (I) can be administered At least one dose of about 180 mg to about 250 mg of the compound, more preferably about 210 mg, is administered daily. The compound may be orally administered to a subject for at least 1 week, 2 weeks, 3 weeks, 4 weeks or more.
[0027] In a preferred embodiment of the invention, a compound of formula (I) or a pharma- ceutically acceptable salt thereof is The salt is orally administered for at least one cycle of a cyclical dosing schedule, Each cycle has a dosing period of at least 10 days, and the compound or a salt thereof is administered for about 80 minutes. In this embodiment, the dosing period is from about 100 mg to about 250 mg per day. , preferably for at least 15 days, more preferably for about 15 to about 25 days, and even more preferably for Preferably, the daily dose is about 80 mg to about 100 mg for about 21 days. is about 100 mg to 140 mg, more preferably about 90 mg or about 120 mg. In another embodiment, the dosing period is preferably at least 15 days, more preferably about 1 Between 5 and about 25 days, and even more preferably about 21 days, the daily dosage is preferably about 140 mg to about 180 mg or about 180 mg to 250 mg, more preferably about In certain embodiments, the dosing period is at least about 160 mg or about 210 mg. The daily dosage is preferably about 80 mg to about 100 mg, more preferably about 90 mg. In another embodiment, the dosing period is at least 15 days and the daily dosage is , about 100 mg to about 140 mg, more preferably about 120 mg. In the method, the dosing period is at least 15 days, and the daily dosage is about 140 mg to about 1 In another embodiment, the dosing period is at least about 80 mg, more preferably about 160 mg. At least 15 days, with a daily dosage of about 180 mg to about 250 mg, more preferably Approximately 210 mg.
[0028] In another preferred embodiment of the present invention, the compound of formula (I) is administered in an amount of about 100 mg of the compound. and a daily dose of about 140 mg to about 140 mg, more preferably about 120 mg, in a cyclical dosing schedule. The subject may be orally administered for at least one cycle, wherein each cycle comprises and a dosing period of about 15 to about 25 days, with the compound being administered daily at the doses mentioned above. The compound and its salts are then administered during a subsequent washout period of about 5 to about 10 days. In certain embodiments of the present invention, the compound of formula (I) is administered in an amount of about 120 mg of the compound. The subject is orally administered a daily dose of wherein each cycle lasts from about 15 to about 25 days, more preferably from about 2 With a dosing period of one day, the compound is administered daily at the doses mentioned above, followed by approximately five days and a rest period of about 10 days, more preferably about 7 days, during which neither compound is administered. In certain embodiments of the present invention, the compound of formula (I) is administered at a daily dose of about 120 mg of the compound. and orally administering to the subject for at least one cycle of the cyclic dosing schedule at a dose of wherein each cycle has a dosing period of about 21 days, and the compound is selected from the group consisting of those mentioned above. The subjects were administered the same dose daily, followed by a rest period of about 7 days during which neither compound was administered. I can't.
[0029] In another preferred embodiment of the present invention, the compound of formula (I) is administered in an amount of from about 80 mg of compound. A daily dose of about 100 mg, more preferably about 90 mg, is generally administered in a cyclical dosing schedule. The subject can be orally administered at least one cycle, wherein each cycle comprises about having a dosing period of 15 to about 25 days, the compound being administered daily at the doses mentioned above; A subsequent washout period of about 5 to about 10 days follows in which neither compound is administered. In certain more particular embodiments, the compound of formula (I) is administered at a daily dose of about 90 mg of the compound. and orally administering the compound to the subject for at least one cycle of the cyclical dosing schedule. wherein each cycle has a dosing period of about 15 to about 25 days, more preferably about 21 days. and the compound is administered daily at the doses mentioned above, followed by about 5 to about 10 days. More preferably, there is a drug holiday of about 7 days during which neither compound is administered. In an embodiment, the compound of formula (I) is administered in a cyclical dosing schedule at a daily dose of about 90 mg of the compound. The subject can be orally administered at least one cycle of The cycle has a dosing period of about 21 days, and the compound is administered daily at the doses mentioned above. followed by a washout period of about 7 days during which neither compound is administered.
[0030] In another preferred embodiment of the present invention, the compound of formula (I) is administered in an amount of about 140 mg of the compound. and a daily dose of about 180 mg, more preferably about 160 mg, in a cyclical dosing schedule. The subject may be orally administered for at least one cycle, wherein each cycle comprises and a dosing period of about 15 to about 25 days, with the compound being administered daily at the doses mentioned above. followed by a washout period of about 5 to about 10 days during which neither compound is administered. In certain embodiments of the invention, the compound of formula (I) is administered at a daily dose of about 160 mg of the compound. and administering to the subject orally for at least one cycle of a cyclic administration schedule. wherein each cycle comprises about 15 to about 25 days of dosing, more preferably about 21 days of dosing. The compound is administered daily at the doses mentioned above, followed by about 5 to about 10 During the rest period of about 7 days, more preferably, no compound is administered. In certain embodiments, the compound of formula (I) is administered at a daily dose of about 160 mg of the compound. The subject may be orally administered the compound during at least one cycle of the periodic dosing schedule. wherein each cycle has a dosing period of about 21 days and the compound is administered at the doses mentioned above. Each dose is administered daily, followed by a washout period of about 7 days during which neither compound is administered.
[0031] In another preferred embodiment of the present invention, the compound of formula (I) is administered in an amount of about 180 mg of the compound. and a daily dose of about 250 mg to about 250 mg, more preferably about 210 mg, in a cyclical dosing schedule. The subject may be orally administered for at least one cycle, wherein each cycle comprises and a dosing period of about 15 to about 25 days, with the compound being administered daily at the doses mentioned above. followed by a washout period of about 5 to about 10 days during which neither compound is administered. In certain embodiments of the invention, the compound of formula (I) is administered at a daily dose of about 210 mg of the compound. and administering to the subject orally for at least one cycle of a cyclic administration schedule. wherein each cycle comprises about 15 to about 25 days of dosing, more preferably about 21 days of dosing. The compound is administered daily at the doses mentioned above, followed by about 5 to about 10 During the rest period of about 7 days, more preferably, no compound is administered. In certain embodiments, the compound of formula (I) is administered at a daily dose of about 210 mg of the compound. The subject may be orally administered the compound during at least one cycle of the periodic dosing schedule. wherein each cycle has a dosing period of about 21 days and the compound is administered at the doses mentioned above. Each dose is administered daily, followed by a washout period of about 7 days during which neither compound is administered.
[0032] In the present invention, the cancers to be treated include, but are not limited to, solid cancers and blood cancers. The solid cancers to be treated in the present invention include soft tissue sarcomas, e.g., liposarcoma, metastatic sarcoma, and sarcoma. cancer, neuroendocrine cancer, adenoid cystic carcinoma, leiomyosarcoma, colorectal cancer, kidney cancer, and lung cancer These include, but are not limited to, thyroid cancer, chordoma, salivary gland carcinoma, adrenal cortical carcinoma, and maxillary sinus adenocarcinoma. The blood cancers treated in the present invention include, but are not limited to, lymphoma. In certain preferred embodiments, the solid cancer to be treated is liposarcoma, e.g., DD or W It may be liposarcoma of type D.
[0033] The compounds of formula (I) can act as MDM2 inhibitors. MDM2 is a cytotoxic molecule that binds to p5 3 Negative regulator of tumor suppressor protein. 90kDa MDM2 protein contains a p53-binding domain in its N-terminus and an E3 ligase that ubiquitinates p53. The C-terminal RING (really interesting The p53 domain is a novel gene domain that regulates cell stimulation and stress-induced upregulation of wild-type p53. Activation leads to binding of MDM2 to p53 at its N-terminus, inhibiting p53 transcriptional activation. This inhibits p53 expression and promotes its degradation via the ubiquitin-proteasome pathway. MDM2 prevents p53-mediated apoptosis and arrests cancer cell proliferation, and inhibits the proliferation of cancer cells. Important oncogenic activities may be attributable to MDM2. In some cases, MDM2 is involved in For example, in cells with alternative splice forms of MDM2, expression independent of the p53 pathway was observed. may cause cancer (HASteinman et al., 2004, J. Biol. Chem., 279(6):4877-4886). In addition, approximately 50% of human cancers are caused by T It has been observed that some people have mutations or deletions in the p53 gene. , melanoma, non-small cell lung cancer (NSCLC), breast cancer, esophageal cancer, leukemia, non-Hodgkin's It is overexpressed in many human cancers, including lymphomas and sarcomas. Overexpression in individuals with sarcoma, glioma, and acute lymphoblastic leukemia (ALL) It has been reported that it is positively correlated with poor prognosis.
[0034] Thus, the cancers treated in the present invention may have an amplified MDM2 gene. Alternatively, it is preferred to have MDM2 overexpressed in cancer. In one embodiment, the cancer to be treated in the present invention is a cancer comprising a gene that is amplified in the cancer genome. The tumor may be a liposarcoma that has the MDM2 gene.
[0035] The cancer to be treated in the present invention has a wild-type TP53 gene in the cancer genome. In a specific embodiment of the present invention, the cancer to be treated in the present invention is , liposarcoma with wild-type TP53 gene in the cancer genome (e.g., DD or W D liposarcoma).
[0036] In a further particular embodiment of the present invention, the cancer to be treated in the present invention is In liposarcoma with wild-type TP53 gene and amplified MDM2 gene in the mouse model, could be.
[0037] In certain of these embodiments, the cancer has a wild-type TP53 gene and and / or cancers with an amplified MDM2 gene, acting as an MDM2 inhibitor can be effectively treated by administration of compounds of formula (I).
[0038] In an embodiment of the invention, a compound of formula (I) or a pharma- ceutically acceptable salt thereof is Also provided is a pharmaceutical composition for use in treating cancer in a subject in need thereof. wherein the pharmaceutical composition comprises about 80 mg to about 250 mg, more preferably about 100 mg from about 140 mg, from about 140 mg to about 180 mg, or from about 180 mg to about 250 mg g of the compound or a salt thereof per day. The compound is orally administered to the subject.
[0039] In an embodiment of the present invention, a method for treating a subject in need thereof comprising administering to the subject a compound of formula (II) A pharmaceutical composition for use in treating cancer is provided, wherein the pharmaceutical composition comprises about 80 mg to about 250 mg, more preferably about 100 mg to about 140 mg, about 140 mg g to about 180 mg, or about 180 mg to about 250 mg of the compound per day The compound is orally administered to the subject according to a dosing schedule comprising administering
[0040] In an embodiment of the present invention, a method for treating a subject in need thereof comprising administering to the subject a compound of formula (II) A pharmaceutical composition of the present invention for use in treating cancer is provided, wherein the pharmaceutical composition The composition may be from about 80 mg to about 250 mg, more preferably from about 100 mg to about 140 mg, A daily dose of 140 mg to about 180 mg, or about 180 mg to about 250 mg of the compound. is orally administered to the subject according to a dosing schedule comprising administering to the subject In certain embodiments, the cancer is liposarcoma, e.g., liposarcoma DD or WD. The daily dose is between about 100 mg and about 140 mg, and the cancer is liposarcoma, e.g., DD or or WD liposarcoma.
[0041] In an embodiment of the invention, a therapeutically effective amount of a compound of formula (I) or a pharma- ceutically acceptable salt thereof is A pharmaceutical composition for use in treating cancer in a subject in need thereof, comprising a salt thereof A composition is provided, wherein the pharmaceutical composition is administered in at least one subgroup of a cyclical administration schedule. The subject is orally administered the drug for at least 10 days and at least 10 days during each cycle. At least 11 days, at least 12 days, at least 13 days, at least 14 days or at least 1 5 day dosing period, and the compound or salt thereof is administered at a daily dose of about 80 mg to about 140 mg. In certain embodiments, the daily dosage is about 100 mg to about 100 mg. In certain embodiments of the present invention, the dosing period is between about 15 days to about 140 mg. For about 25 days, more preferably for about 21 days. The duration is between about 15 and about 25 days, and the daily dosage is between about 100 mg and about 140 mg. In certain embodiments of the invention, the dosing period is about 21 days and the daily dosage is The dosage is about 100 mg to about 140 mg, the duration of administration is about 15 days to about 25 days, and The daily dosage is about 120 mg, or the dosing period is about 21 days, and the daily dosage is about 12 0mg.
[0042] In an embodiment of the invention, a therapeutically effective amount of a compound of formula (I) or a pharma- ceutically acceptable salt thereof is A pharmaceutical composition for use in treating cancer in a subject in need thereof, comprising a salt thereof A composition is provided, wherein the pharmaceutical composition is administered in at least one subgroup of a cyclical administration schedule. The subject is orally administered the drug for at least 10 days and at least 10 days during each cycle. At least 11 days, at least 12 days, at least 13 days, at least 14 days or at least 1 The compound or salt thereof is administered at a daily dose of about 140 mg to about 180 mg over a 5-day dosing period. In a specific embodiment of the invention, the dosing period is about 15 days. In certain embodiments of the present invention, the method comprises the steps of: The dosing period is between about 15 and about 25 days, and the daily dosage is between about 140 mg and about 180 mg. In certain embodiments of the invention, the dosing period is about 21 days and the daily The dosage is about 140 mg to about 180 mg, and the duration of administration is about 15 to about 25 days. and the daily dosage is about 160 mg, or the duration of administration is about 21 days, and The daily dosage is approximately 160 mg.
[0043] In an embodiment of the invention, a therapeutically effective amount of a compound of formula (I) or a pharma- ceutically acceptable salt thereof is A pharmaceutical composition for use in treating cancer in a subject in need thereof, comprising a salt thereof A composition is provided, wherein the pharmaceutical composition comprises at least one subgroup of a cyclic administration schedule. The subject is orally administered the drug for at least 10 days during each cycle, wherein each cycle is at least At least 11 days, at least 12 days, at least 13 days, at least 14 days or at least 1 The compound or salt thereof is administered at a daily dose of about 180 mg to about 250 mg over a 5-day dosing period. In certain embodiments of the present invention, the dosing period is about 15 days. In certain embodiments of the present invention, the method comprises the steps of: The dosing period is between about 15 and about 25 days, and the daily dosage is between about 180 mg and about In certain embodiments of the invention, the dosing period is about 21 days, and The daily dosage is about 180 mg to about 250 mg, and the administration period is about 15 to about 25 days. and the daily dosage is about 210 mg, or the dosing period is about 21 days, or The daily dosage is approximately 210 mg.
[0044] In an embodiment of the invention, a therapeutically effective amount of a compound of formula (I) or a pharma- ceutically acceptable salt thereof is A pharmaceutical composition for use in treating cancer in a subject in need thereof, comprising a salt thereof A composition is provided, wherein the pharmaceutical composition is administered in at least one subgroup of a cyclical administration schedule. The subject is orally administered the drug for at least 10 days and at least 10 days during each cycle. At least 11 days, at least 12 days, at least 13 days, at least 14 days or at least 1 5 day dosing period, and the compound or salt thereof is administered at a daily dose of about 80 mg to about 100 mg. In certain embodiments of the invention, the dosing period is about 15 days or In certain embodiments of the present invention, the administration The duration of the medication is about 21 days and the daily dosage is about 80 mg to about 100 mg.
[0045] In an embodiment of the invention, a therapeutically effective amount of a compound of formula (I) or a pharma- ceutically acceptable salt thereof is A pharmaceutical composition for use in treating cancer in a subject in need thereof, comprising a salt thereof A composition is provided, wherein the pharmaceutical composition is administered in at least one subgroup of a cyclical administration schedule. The subject is orally administered 50 mg of 10 ... or a dosing period of about 21 days, and the compound or salt thereof is administered in an amount of about 100 mg to about 140 mg. mg, more preferably about 120 mg daily, followed by about 5 days of The compound and its salts are administered in a rest period of about 10 days, preferably about 7 days. Not given.
[0046] In an embodiment of the invention, a therapeutically effective amount of a compound of formula (I) or a pharma- ceutically acceptable salt thereof is The present invention relates to a method for treating cancer in a subject in need thereof, comprising administering to said subject a salt thereof A pharmaceutical composition of the present invention is provided, wherein the pharmaceutical composition is administered in a cyclical administration schedule of at least orally administered for one cycle, each cycle having a dosing period of about 21 days; The compound or salt thereof is administered in an amount of about 100 mg to about 140 mg, more preferably about 120 mg. is administered daily to the subject at a daily dosage of about 7 days followed by a washout period of about 7 days. None of the salts are administered.
[0047] In an embodiment of the invention, a therapeutically effective amount of a compound of formula (I) or a pharma- ceutically acceptable salt thereof is A pharmaceutical composition for use in treating cancer in a subject in need thereof, comprising a salt thereof A composition is provided, wherein the pharmaceutical composition is administered in at least one subgroup of a cyclical administration schedule. The subject is orally administered 50 mg of 10 ... or a dosing period of about 21 days, and the compound or salt thereof is administered in an amount of about 140 mg to about 180 mg. mg, more preferably about 160 mg daily, followed by about 5 days of The compound and its salts are administered in a rest period of about 10 days, preferably about 7 days. Not given.
[0048] In an embodiment of the invention, a therapeutically effective amount of a compound of formula (I) or a pharma- ceutically acceptable salt thereof is The present invention relates to a method for treating cancer in a subject in need thereof, comprising administering to said subject a salt thereof A pharmaceutical composition of the present invention is provided, wherein the pharmaceutical composition is administered in a cyclical administration schedule of at least orally administered for one cycle, each cycle having a dosing period of about 21 days; The compound or salt thereof is administered in an amount of about 140 mg to about 180 mg, more preferably about 160 mg. is administered daily to the subject at a daily dosage of about 7 days followed by a washout period of about 7 days. None of the salts are administered.
[0049] In an embodiment of the invention, a therapeutically effective amount of a compound of formula (I) or a pharma- ceutically acceptable salt thereof is A pharmaceutical composition for use in treating cancer in a subject in need thereof, comprising a salt thereof A composition is provided, wherein the pharmaceutical composition is administered in at least one subgroup of a cyclical administration schedule. The subject is orally administered 50 mg of 10 ... or a dosing period of about 21 days, and the compound or salt thereof is administered in an amount of about 180 mg to about 250 mg. mg, more preferably about 210 mg daily, followed by about 5 days of The compound and its salts are administered in a rest period of about 10 days, preferably about 7 days. Not given.
[0050] In an embodiment of the invention, a therapeutically effective amount of a compound of formula (I) or a pharma- ceutically acceptable salt thereof is The present invention relates to a method for treating cancer in a subject in need thereof, comprising administering to said subject a salt thereof A pharmaceutical composition of the present invention is provided, wherein the pharmaceutical composition is administered in a cyclical administration schedule of at least orally administered for one cycle, each cycle having a dosing period of about 21 days; The compound or salt thereof is administered in an amount of about 180 mg to about 250 mg, more preferably about 210 mg. is administered daily to the subject at a daily dosage of about 7 days followed by a washout period of about 7 days. None of the salts are administered.
[0051] In an embodiment of the invention, a therapeutically effective amount of a compound of formula (I) or a pharma- ceutically acceptable salt thereof is A pharmaceutical composition for use in treating cancer in a subject in need thereof, comprising a salt thereof A composition is provided, wherein the pharmaceutical composition is administered in at least one subgroup of a cyclical administration schedule. The subject is orally administered 50 mg of 10 ... or a dosing period of about 21 days, and the compound or a salt thereof is administered at a dose of about 80 mg to about 100 mg. g, more preferably about 90 mg daily, followed by about 5 days The compound and its salts are administered during a rest period of about 10 days, preferably about 7 days. I can't.
[0052] In an embodiment of the invention, a therapeutically effective amount of a compound of formula (I) or a pharma- ceutically acceptable salt thereof is The present invention relates to a method for treating cancer in a subject in need thereof, comprising administering to said subject a salt thereof A pharmaceutical composition of the present invention is provided, wherein the pharmaceutical composition is administered in a cyclical administration schedule of at least orally administered for one cycle, each cycle having a dosing period of about 21 days; The compound or salt thereof is administered in an amount of about 80 mg to about 100 mg, more preferably about 90 mg. The compound and its salts are administered to the subject daily at a daily dosage of 100 mg / kg / day, followed by a washout period of about 7 days. Neither of these will be administered.
[0053] In an embodiment of the present invention, a therapeutically effective amount of a compound of formula (II) is provided. The pharmaceutical composition of the present invention is provided for use in treating cancer in a subject, The pharmaceutical composition is administered to a subject during at least one cycle of the cyclic administration schedule. orally, where each cycle is administered for about 15 to about 25 days, preferably about 21 days. and the compound is administered in a dose of about 80 mg to about 140 mg, preferably about 100 mg to about More preferably, the daily dosage is about 140 mg, more preferably about 120 mg, followed by about 5 days of During the rest period of about 10 days, preferably about 7 days, the compound is not administered. In certain embodiments, the daily dosage is between about 100 mg and about 140 mg, and the dosing period is The drug withdrawal period is between about 15 and about 25 days, and between about 5 and about 10 days. In another particular embodiment of the present invention, the daily dosage is about 120 mg and the duration of dosing is about 15 The drug-free period is between about 5 and about 10 days. In certain embodiments, the daily dosage is between about 100 mg and about 140 mg, and the dosing period is In another particular embodiment of the present invention, the interval between doses is about 21 days and the drug holiday is about 7 days. The daily dosage is about 120 mg, the dosing period is about 21 days, and the drug-free period is about 7 days. .
[0054] In an embodiment of the present invention, a therapeutically effective amount of a compound of formula (II) is provided. The pharmaceutical composition of the present invention is provided for use in treating cancer in a subject, The pharmaceutical composition is administered to a subject during at least one cycle of the cyclic administration schedule. orally, where each cycle is administered for about 15 to about 25 days, preferably about 21 days. and the compound has a dosage of about 140 mg to about 180 mg, more preferably about 160 mg. followed by a rest period of about 5 to about 10 days, preferably about 7 days. In certain embodiments of the invention, the daily dosage is about between about 140 mg and about 180 mg, and the duration of administration is between about 15 days and about 25 days; The drug holiday period is between about 5 days and about 10 days. In another specific embodiment of the present invention, The dosage is about 160 mg, the dosing period is between about 15 and about 25 days, and the drug-free period is Between about 5 and about 10 days. In another specific embodiment of the invention, the daily dosage is about The dose ranges from 140 mg to approximately 180 mg, with a dosing period of approximately 21 days and a drug-free period of approximately 7 days. In another specific embodiment of the invention, the daily dosage is about 160 mg, The duration is approximately 21 days, with a drug-free period of approximately 7 days.
[0055] In an embodiment of the present invention, a therapeutically effective amount of a compound of formula (II) is provided. The pharmaceutical composition of the present invention is provided for use in treating cancer in a subject, The pharmaceutical composition is administered to a subject during at least one cycle of the cyclic administration schedule. orally, where each cycle is administered for about 15 to about 25 days, preferably about 21 days. and the compound has a dosage of about 180 mg to about 250 mg, more preferably about 210 mg. followed by a rest period of about 5 to about 10 days, preferably about 7 days. In certain embodiments of the invention, the daily dosage is about between about 180 mg and about 250 mg, and the duration of administration is between about 15 days and about 25 days; The drug holiday period is between about 5 days and about 10 days. In another specific embodiment of the present invention, The dosage is about 210 mg, the dosing period is between about 15 and about 25 days, and the drug holiday period is Between about 5 and about 10 days. In another specific embodiment of the invention, the daily dosage is about The dose is between 180 mg and approximately 250 mg, with a dosing period of approximately 21 days and a drug-free period of approximately 7 days. In another specific embodiment of the invention, the daily dosage is about 180 mg, The duration is approximately 21 days, with a drug-free period of approximately 7 days.
[0056] In an embodiment of the present invention, a therapeutically effective amount of a compound of formula (II) is provided. The pharmaceutical composition of the present invention is provided for use in treating cancer in a subject, The pharmaceutical composition is orally administered during at least one cycle of the cyclic administration schedule. wherein each cycle has a dosing period of about 15 to about 25 days, preferably about 21 days. The compound or salt thereof is administered in an amount of about 80 mg to about 140 mg, preferably about 100 mg to about 140 mg. and preferably about 140 mg, more preferably about 120 mg, followed by about 5 a drug holiday of about 10 days, preferably about 7 days, in which the compound is not administered; The cancer is liposarcoma, e.g., liposarcoma DD or WD. In this study, the daily dosage is between about 100 mg and about 140 mg, and the duration of administration is about 15 days. The drug holiday period is between about 5 and about 10 days. In an embodiment, the daily dosage is about 120 mg and the dosing period is about 15 to about 25 days. In another specific embodiment of the present invention, the drug holiday is between about 5 days and about 10 days. In this study, the daily dosage is between about 100 mg and about 140 mg, and the duration of administration is about 21 days. and the drug holiday is about 7 days. In another specific embodiment of the invention, the daily dosage is about The dose is 120 mg, the dosing period is approximately 21 days, and the drug holiday period is approximately 7 days.
[0057] In an embodiment of the present invention, a therapeutically effective amount of a compound of formula (II) is provided. The pharmaceutical composition of the present invention is provided for use in treating cancer in a subject, The pharmaceutical composition is orally administered during at least one cycle of the cyclic administration schedule. wherein each cycle has a dosing period of about 15 to about 25 days, preferably about 21 days. The compound or salt thereof may be administered in an amount of about 140 mg to about 180 mg, more preferably about 160 mg. mg daily, followed by about 5 to about 10 days, preferably about 7 days of rest. During the drug phase, the compound is not administered, and the cancer is liposarcoma, e.g., DD or In certain embodiments of the present invention, the daily dosage is about 140 mg to The dosage period is between about 15 and about 25 days, and the drug holiday period is about In another specific embodiment of the present invention, the daily dosage is about 1 60 mg, the dosing period is about 15 to about 25 days, and the drug holiday period is about 5 to about In another specific embodiment of the invention, the daily dosage is from about 140 mg to about 10 days. The dose ranges from about 1 to about 180 mg, the dosing period is about 21 days, and the drug holiday period is about 7 days. In another particular embodiment of the present invention, the daily dosage is about 160 mg and the duration of dosing is about 21 The drug-free period is approximately 7 days.
[0058] In an embodiment of the present invention, a therapeutically effective amount of a compound of formula (II) is provided. The pharmaceutical composition of the present invention is provided for use in treating cancer in a subject, The pharmaceutical composition is orally administered during at least one cycle of the cyclic administration schedule. wherein each cycle has a dosing period of about 15 to about 25 days, preferably about 21 days. The compound or salt thereof may be administered in an amount of about 180 mg to about 250 mg, more preferably about 210 mg. mg daily, followed by about 5 to about 10 days, preferably about 7 days of rest. During the drug phase, the compound is not administered, and the cancer is liposarcoma, e.g., DD or W. In certain embodiments of the present invention, the daily dosage is about 180 mg to The dose ranges from about 250 mg to about 15 days and the drug holiday period is about 5 days. In another specific embodiment of the present invention, the daily dosage is between about 21 The dosage period is about 15 to about 25 days, and the drug holiday period is about 5 to about 10 days. In another specific embodiment of the present invention, the daily dosage is between about 180 mg and 0 days. The dosage is between about 250 mg, the on-dose period is about 21 days, and the off-dose period is about 7 days. In another specific embodiment, the daily dosage is about 210 mg and the dosing period is about 21 days. The drug holiday period is approximately 7 days.
[0059] In an embodiment of the present invention, a therapeutically effective amount of a compound of formula (II) is provided. The pharmaceutical composition of the present invention is provided for use in treating cancer in a subject, The pharmaceutical composition is administered to a subject during at least one cycle of the cyclic administration schedule. orally, where each cycle is administered for about 15 to about 25 days, preferably about 21 days. The compound or salt thereof has a drug duration of about 80 mg to about 100 mg of the compound, more preferably or daily at a daily dosage of about 90 mg, followed by about 5 to about 10 days, preferably During the approximately 7 day drug holiday, the compound is not administered. The daily dosage is about 90 mg, the dosing period is between about 15 and about 25 days, and the drug holiday period is between about 15 and about 25 days. In another specific embodiment of the invention, the daily dosage is between about 5 days and about 10 days. The dose is between about 80 mg and about 100 mg, the dosing period is about 21 days, and the drug holiday period is about 7 days. In another specific embodiment of the invention, the daily dosage is about 90 mg and the dosing period is The interval between doses is approximately 21 days, with a drug-free period of approximately 7 days.
[0060] In an embodiment of the present invention, a therapeutically effective amount of a compound of formula (II) is provided. The pharmaceutical composition of the present invention is provided for use in treating cancer in a subject, The pharmaceutical composition is orally administered during at least one cycle of the cyclic administration schedule. wherein each cycle has a dosing period of about 15 to about 25 days, preferably about 21 days. and the compound or salt thereof is administered daily at a daily dosage of about 80 mg to about 100 mg of the compound. followed by a drug holiday of about 5 to about 10 days, preferably about 7 days, is not administered, and wherein the cancer is liposarcoma, e.g., liposarcoma of DD or WD. In a particular embodiment of the invention, the daily dosage is about 90 mg and the duration of administration is about 15 days. The drug holiday period is between about 5 and about 10 days. In an embodiment, the daily dosage is between about 80 mg and about 100 mg, and the dosing period is about In another specific embodiment of the present invention, the daily dosing period is about 21 days and the drug holiday period is about 7 days. The dosage is about 90 mg, the dosing period is about 21 days, and the drug holiday period is about 7 days.
[0061] In an embodiment of the invention, the pharmaceutical composition comprises a pharma- ceutical acceptable excipient (e.g., vehicle). Additives such as crusts, adjuvants and extenders, viscosity enhancers, adhesives, plasticizers, binders, Disintegrants, tablet lubricants, glidants, coating agents, antioxidants, preservatives, moisturizers, opacifiers , glazes, sweeteners, aromas, flavorings, and colorings), and It can be prepared as a composition.
[0062] The pharmaceutical compositions of the present invention can be formulated by those skilled in the art. The pharmaceutical compositions for administration may be in the form of tablets, powders, granules, capsules, pills, lozenges, solutions, etc. , syrups, elixirs, emulsions, and oily or aqueous suspensions. The pharmaceutical solution may be prepared using a pharma- ceutical acceptable acid, such as p-toluenesulfonic acid. , by forming an acid addition salt.
[0063] Compounds of formula (I) or (II) are incorporated herein by reference in their entirety. The method is described in Example 70 of WO2012 / 121361 and WO2014 / 038606. The compound of formula (II) can be easily prepared by a person skilled in the art according to Example 7 of the above. , can be prepared in crystalline form.
[0064] In another embodiment of the present invention, a method is provided for the treatment of cancer in a subject in need thereof. A therapeutically effective amount of a compound of formula (I) or a pharma- ceutically acceptable salt thereof according to a drug schedule. orally administering daily to a subject, wherein the dosing schedule comprises and administering to the subject a daily dose of about 80 mg to about 250 mg of the compound or a salt thereof. In a preferred embodiment of the dosing schedule, the daily dose of the compound or salt thereof is , preferably between about 100 mg and about 140 mg, more preferably about 120 mg. In a preferred embodiment of the dosing schedule, the daily dose of the compound or salt thereof is preferably Or between about 140 mg and about 180 mg, more preferably about 160 mg. In a preferred embodiment of the schedule, the daily dose of the compound or salt thereof is preferably Between about 180 mg and about 250 mg, more preferably about 210 mg. In a preferred embodiment of the present invention, the daily dose of the compound or salt thereof is preferably about 80 In a preferred embodiment, the amount is between about 90 mg and about 100 mg. The cancer being treated is liposarcoma, specifically the MDM2 gene amplified in the liposarcoma genome. In a preferred embodiment, the compound of formula (I) is The physiologically acceptable salt may be a compound of formula (II).
[0065] In an embodiment of the invention, there is provided a method of treating cancer in a subject in need thereof. Thus, during at least one cycle of the cyclic administration schedule, a therapeutically effective amount of a compound of formula (I) or a pharma- ceutical acceptable salt thereof. wherein each cycle has a dosing period of 15 to 25 days, and the compound or salt thereof is daily at a daily dosage of about 80 mg to about 250 mg of the compound or a salt thereof, followed by During the five to ten day washout period, neither the compound nor its salts are administered. In a preferred embodiment of the schedule, the daily dose of the compound or salt thereof is preferably The dosage schedule is between about 100 mg and about 140 mg, more preferably about 120 mg. In a preferred embodiment of the present invention, the daily dose of the compound or salt thereof is preferably about 1 Between 40 mg and about 180 mg, more preferably about 160 mg. Dosing Schedule In a preferred embodiment, the daily dose of the compound or salt thereof is preferably about 180 mg. In a preferred embodiment, the amount is between about 210 mg and about 250 mg. The cancer being treated is liposarcoma, specifically the MDM2 gene amplified in the liposarcoma genome. In a preferred embodiment, the compound of formula (I) is The physiologically acceptable salt may be a compound of formula (II).
[0066] The compounds of formula (I) or (II) may be used in combination with additional antitumor agents. The compounds of formula (I) or (II) may be used in combination with additional antitumor agents. Examples include antitumor antibiotics, antitumor plant compounds, BRMs (biological response modifiers), and hormones. The preferred embodiments of the present invention include, but are not limited to, anti-tumor agents, vitamins, anti-tumor antibodies, molecular targeted drugs, and other anti-tumor agents. In an embodiment, the antitumor agents used in combination with the compounds of formula (I) or (II) The agent may or may not be an MDM2 inhibitor.
[0067] More specifically, examples of alkylating agents include: alkylating agents, e.g. Nitrogen mustard, nitrogen mustard N-oxide, bendamustine and chlorambucil; amidine alkylating agents, such as carboquone and thiotepa; oxide alkylating agents, such as dibromomannitol and dibromodulcitol; nitro Sourea alkylating agents, such as carmustine, lomustine, semustine, nimustine hydrochloride , streptozotocin, chlorozotocin, and ranimustine; and busulfan, in Prosulfant tosylate, and dacarbazine.
[0068] Examples of various antimetabolites include: purine antimetabolites, e.g., 6 -Mercaptopurine, 6-thioguanine, and thioinosine; pyrimidine antimetabolites , e.g. fluorouracil, tegafur, tegafur-uracil, carmofur, doxycycline Fluridine, broxuridine, cytarabine, and enocitabine; and antifolates Substances such as methotrexate and trimetrexate.
[0069] Examples of antitumor antibiotics include mitomycin C, bleomycin, peplomycin, Daunorubicin, aclarubicin, doxorubicin, idarubicin, pirarubicin, TH P-adriamycin, 4'-epidoxorubicin, and epirubicin; and chromo Examples include actinomycin A3 and actinomycin D.
[0070] Examples of anti-tumor plant ingredients and their derivatives include: Vinca alkaloides loids, such as vindesine, vincristine, and vinblastine; taxanes, such as Paclitaxel, docetaxel, and cabazitaxel; and epipodophyllotoxins , such as etoposide and teniposide.
[0071] Examples of BRMs include tumor necrosis factor and indomethacin.
[0072] Examples of hormones include hydrocortisone, dexamethasone, methylprednisolone, Prednisolone, prasterone, betamethasone, triamcinolone, oxymetholone, na Androlone, Methenolone, Fosfestrol, Ethinylestradiol, Chlormadil Non, medroxyprogesterone, and mepitiostane.
[0073] Examples of vitamins include vitamin C and vitamin A.
[0074] Examples of antitumor antibodies and molecular targeted drugs include trastuzumab, rituximab, and cetaxel. Mab, nimotuzumab, denosumab, bevacizumab, infliximab, ipilimumab, Volumab, pembrolizumab, avelumab, pidilizumab, atezolizumab, ramucirumab imatinib mesylate, dasatinib, gefitinib, erlotinib, sunitinib, laparoscopic Patinib, vemurafenib, dabrafenib, trametinib, pazopanib, palbocycline bromide, panobinostat, sorafenib, ibrutinib, bortezomib, carfilzomib , ixazomib, and quizartinib.
[0075] Examples of other antitumor agents include cisplatin, carboplatin, oxaliplatin, and tamoxifen. Xifene, Letrozole, Anastrozole, Exemestane, Toremifene Citrate Salt, fulvestrant, bicalutamide, flutamide, mitotane, leuprorelin, gossypium Relin acetate, camptothecin, ifosfamide, cyclophosphamide, melphalan, L-asparaginase, aceglatone, schizofuran, picibanil, procarbazine, Pobroman, neocarzinostatin, hydroxyurea, ubenimex, azacitidine, dexamethasone Citabine, thalidomide, lenalidomide, pomalidomide, eribulin, tretinoin, and krestin.
[0076] The following examples are provided for illustrative purposes only and are not intended to limit the invention. It is understood that: Example 1
[0077] This example demonstrates that a particular dosing regimen for a test compound (also referred to as "Compound 2") is Describes clinical studies that have shown unexpectedly positive results in the treatment of cancer.
[0078] Test Compounds (3'R,4'S,5'R)-N-[(3R,6S)-6-Carbamoyltetrahydro- 2H-pyran-3-yl]-6”-chloro-4'-(2-chloro-3-fluoropyridine -4-yl)-4,4-dimethyl-2”-oxo-1”,2”-dihydrodispiro[cyclo Hexane-1,2'-pyrrolidine-3',3”-indole]-5'-carboxamide Mono(4-methylbenzenesulfonate) monohydrate (Compound 2) is hereby incorporated by reference. WO2012 / 121361 and WO201 The mixture was prepared as described in US Pat. No. 4 / 038606.
[0079] Eligibility Criteria Inclusion Criteria for Solid Tumor / Lymphoma Subjects: 1. Relapsed or refractory to standard treatment or Histologically or cytologically documented progression for which no standard treatment is available have a chronic solid tumor or lymphoma. 2.Male or female, aged 18 or older. 3.Eastern Cooperative Oncology Group(ECO) G) performance status of 0 to 1. 4. Have adequate bone marrow function, adequate kidney function, adequate liver function, and adequate blood clotting function. do.
[0080] The demographics / characteristics of subjects enrolled in the dose escalation portion of the study are summarized in Table 1 It was. [Table 1]
[0081] Dosage regimen Compound 2 is mixed with a pharma- ceutically acceptable carrier (including excipients, plasticizers, disintegrants and lubricants). Compound 2 was administered as an oral capsule containing the active ingredient (a 28-day anti-inflammatory drug) on days 1 to 21 of a 28-day cycle. Subjects were dosed once daily on day 21 (QD21 / 28). The drug administration schedule may be adjusted using the schedules described above for solid tumors and / or lymphomas. The maximum tolerated dose (MTD) of Compound 2 in the subjects was determined and then examined. Compound 2 was administered under fasting conditions by abstaining from food for 2 hours before and 1 hour after feeding. The dose escalation of compound 2 to determine the MTD was performed according to the dose escalation principle with overdose limit ( A modified Bayesian logistic regression model (BLRM) followed by EWOC Dose escalation was guided by a modified continuous reassessment method (mCRM). 15 mg / day based on the High Non-Serious Toxicity Dose (HNSTD) of 100 g / kg The study was initiated in subjects with advanced solid tumors or lymphomas at a starting dose of Compound 2 of .
[0082] Definition of dose-limiting toxicity DLT was assessed during the observation period in each dose level cohort (cycle 1 Any treatment-emergent disease that cannot be attributed to a disease or disease-related process occurring during The TEAEs were defined as group-specific adverse events (TEAEs) according to NCI CTCAE version 4. As a result of non-disease-related adverse events (AEs) of grade 2 or higher , at least 7 of the prescribed doses of Compound 2 in the first 21 days (i.e., day 16) Subjects who failed to complete 5% were considered to have DLT.
[0083] Tumor assessment Every 2 cycles while subjects remain on study for the first 9 cycles, and and every 3 cycles thereafter (starting with cycles 3, 5, 7, and 9, then cycle 12, Tumor assessments were performed at baseline within 15 days of enrollment.
[0084] Tumor re-biopsy To explore possible mechanisms of acquired resistance to compound 2, Tumor repeat biopsy achieved initial complete / partial response by standard response criteria, but During the treatment, preferably before initiating a new therapy, the patient may be treated with chemotherapy for subjects who subsequently develop progressive disease. This was done within 30 days following the last dose of Compound 2 treatment.
[0085] TP53 genotyping, subject enrollment and early discontinuation options Tumor TP53 genotyping was performed on archived formalin-positive tumors in all enrolled subjects. Fixed paraffin-embedded (FFPE) or frozen samples were used. Confirmation of phenotype status was not required prior to Compound 2 dosing. The subject was subsequently found to contain a nonsynonymous mutation, insertion, or deletion in the TP53 gene. In the event that this occurs, investigators and subjects will be informed of the genotyping results and Patients were given the option to discontinue the study drug at any time.
[0086] Research period The number of treatment cycles was not fixed in this study. Continue to derive clinical benefit from treatment in the absence of relapse, progression, or unacceptable toxicity The subjects continued treatment at the discretion of the physician. Patients were treated with targeted therapy and data on treated patients were collected in a separate database.
[0087] treatment group In an open-label, single-arm, dose-escalation study, each subject received 2 doses of Compound 2. The drug was given orally once daily on days 1 to 21 of an 8-day cycle.
[0088] Safety parameters The safety profile included AEs, physical examination findings, and vital signs. The clinical outcomes were based on clinical laboratory measurements, and ECG recordings. All subjects who underwent were included in the safety analysis.
[0089] Tumor response Response assessments were performed according to treatment schedule or if disease progression was suspected. Radiographic evaluation included computed tomography (CT) of all affected areas. In addition, subjects with lymphoma were included. 18 F) Deoxyglucose fluoride - Patients with solid tumors underwent positron emission tomography (FDG-PET) scans. RECIST 1.1 criteria for subjects with lymphoma and revised I criteria for subjects with lymphoma The tumor was assessed by the physician according to the WG criteria. Descriptive statistics for the percentage change in scores on SLD for each subject were provided. Waterfall plot of maximum percent change from lean in patients with advanced solid malignancies In addition, FDG-PET scans were performed in subjects with lymphoma. Descriptive statistics for lymphoma were provided for subjects with lymphoma according to the revised IWG criteria.
[0090] result Thirty-four subjects were enrolled in the dose-escalation portion of the Phase 1 study, of which 31 subjects were Subjects were evaluable for DLT. Subjects ranged in age from 42 to 79 years. The median age was 59.5 years. Subjects had 13 different tumor types: Of these, 76.5% were TP53 wild-type, most commonly in patients with liposarcoma who were enrolled in the study. The drug was administered Q10 on 21 days of a 28-day cycle. D schedule (QD 21 / 28) starting at 15 mg, then 30, 60, 120 and Seven increasing dose levels were studied, ranging from 160 mg to the highest tested dose of 240 mg. 90% of patients on an alternative schedule of daily dosing in a 28-day cycle (QD28 / 28) The maximum tolerated dose (MTD) was determined to be 120 mg QD21 / 21. In the QD28 / 28 schedule, 2 of 13 subjects had DLT. The 90 mg dose in this schedule was also determined to be the MTD for this dosing schedule. , 1 of 9 subjects experienced a DLT.
[0091] Twenty-three subjects were evaluable for efficacy per RECIST v1.1 in this study. The majority of subjects (21 of 23) had a mean score of >10% in 3 subjects. Most patients experienced stable disease (SD) with tumor shrinkage as the best tumor response (Figure 1). Patients showed sustained stabilization of their disease, with median progression-free survival (PFS) of 5. Interestingly, the greatest tumor shrinkage and most durable stable disease occurred in The results were seen for subjects with well-differentiated or dedifferentiated (WD / DD) liposarcoma ( Table 2 The 3- and 6-month PFS rates in patients with liposarcoma were 91.7% and 92.2%, respectively. The 12-month PFS rate in patients with liposarcoma was 57.3% and 76.4%, respectively (Table 2). It is even more noteworthy that the results showed that ganization of Research and Treatment of The European Organization for Research and Technology Cancer (EORTC) has determined that 12-week PFS is greater than 40% in second-line patients. We have defined criteria for active agents in soft tissue sarcomas. Our efficacy results in compared favorably with historical data. [Table 2]
[0092] Treatment-emergent adverse events of any grade in any treatment cycle unrelated to causality TEAEs were observed in 97.1% of subjects, of which 55.9% were gray matter. The most common TEAEs of unrelated causality were neutropenia, (17.6%), thrombocytopenia (32.4%), anemia (38.2%), nausea (64.7%) ), vomiting (35.3%), diarrhea (35.3%), constipation (23.5), loss of appetite (50.0 %), taste disorder (20.6%), fatigue (52.9%), shortness of breath (26.5%), and hypoalcoholism (20.6%). The most common symptoms were hyperglycemia (32.4%), peripheral edema (17.6%), and hyperglycemia (29.4%). The most common drug-related TEAEs were due to on-target toxic effects of MDM2 inhibitors. Concordant, hematological (thrombocytopenia, anemia, neutropenia), gastrointestinal (nausea, , vomiting and diarrhea), and fatigue [Lillian L. Siu et al., J Clin On col 32:5s, 2014 (suppl; abstr 2535) and Isa belle Ray-Coquard et al., The Lancet Oncology, 1 3(11):1133-1140 (November 2012)]. 4 weeks Prolonged thrombocytopenia leading to dose discontinuation or interruption of > 10 days occurred in 8 subjects. Two patients were treated at the MTD of 120 mg QD 21 / 28. 9 of 13 subjects in the 90 mg QD 28 / 28 group and 6 of 9 subjects in the 90 mg QD 28 / 28 group (MTD for two dosing schedules) is based on the Common Terminology Criteria for Adverse Events (CTCAE) v4 0.0 Grade ≥3 TEAEs were experienced, most notably thrombocytopenia (Table 3). A total of 6 subjects experienced DLTs, all at doses equal to or greater than the MTD (Table 4). All three DLTs at MTD were endothelial thromboembolisms resulting in delays of >1 week in cycle 2. Patients with hematological malignancies tolerated 160 mg. Ta.
[0093] [Table 3]
[0094] [Table 4]
Claims
1. A therapeutically effective amount of a compound of formula (I) or a pharma- ceutical acceptable salt thereof is administered to a subject in need thereof.
23. A pharmaceutical composition for use in treating cancer in a subject, comprising about 80 mg or more of a dosing schedule comprising administering to a subject a daily dose of from about 250 mg to about 250 mg of the compound or a salt thereof. Orally administered pharmaceutical composition according to the 【Chemistry 1】 (3'R,4'S,5'R)-N-[(3R,6S)-6-carbamoyltetrahydro- 2H-pyran-3-yl]-6"-chloro-4'-(2-chloro-3-fluoropyridine -4-yl)-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclo[(1,2-dihydro- Hexane-1,2'-pyrrolidine-3',3"-indole-5'-carboxamide 。
2. The dosing schedule comprises administering a daily dose of about 80 mg to about 140 mg of the compound or a salt thereof. The pharmaceutical composition of claim 1 , comprising administering the composition to a subject.
3. The dosing schedule comprises administering a daily dose of about 80 mg to about 100 mg of the compound or a salt thereof. The pharmaceutical composition of claim 1 , comprising administering the composition to a subject.
4. The dosing schedule provides for administering to the subject a daily dose of about 90 mg of the compound or a salt thereof. The pharmaceutical composition of claim 1 ,
5. The dosing schedule is a daily dose of about 100 mg to about 140 mg of the compound or a salt thereof. The pharmaceutical composition of claim 1, comprising administering to a subject.
6. The dosing schedule administers to the subject a daily dose of about 120 mg of the compound or a salt thereof. The pharmaceutical composition of claim 1 , comprising:
7. The method according to any one of claims 1 to 6, wherein the cancer is liposarcoma. A pharmaceutical composition for use in treating cancer in an elephant.
8. The cancer is a liposarcoma having an amplified MDM2 gene in the liposarcoma genome. Item 8. The pharmaceutical composition for use in treating cancer in a subject in need thereof according to Item 7. Composition.
9. A therapeutically effective amount of a compound of formula (I) or a pharma- ceutical acceptable salt thereof is administered to a subject in need thereof. A pharmaceutical composition for use in treating cancer in a subject, comprising a cyclic administration schedule. The drug is administered orally for at least one cycle of the schedule, each cycle comprising at least The compound or salt thereof is administered at a daily dose of about 80 mg to about 250 mg over a 10 day dosing period. A pharmaceutical composition administered daily in a dosage amount.
10. The compound or a salt thereof is administered daily in a daily dosage of about 80 mg to about 140 mg. The pharmaceutical composition according to claim 9.
11. The compound or a salt thereof is administered daily in a daily dosage of about 80 mg to about 100 mg. The pharmaceutical composition according to claim 9.
12. 10. The method of claim 9, wherein the compound or salt thereof is administered daily at a daily dosage of about 90 mg. Pharmaceutical compositions.
13. The compound or a salt thereof is administered daily in a daily dosage of about 100 mg to about 140 mg. The pharmaceutical composition according to claim 9.
14. 10. The method of claim 9, wherein the compound or salt thereof is administered daily at a daily dosage of about 120 mg. A pharmaceutical composition comprising:
15. About 140 mg to about 180 mg, more preferably about 160 mg, of the compound or its salt. The pharmaceutical composition of claim 9, wherein the pharmaceutical composition is administered daily at a daily dosage of
16. 10. The method of claim 9, wherein the compound or salt thereof is administered daily in a daily dosage of about 160 mg. A pharmaceutical composition comprising:
17. About 180 mg to about 250 mg, more preferably about 210 mg, of the compound or its salt. The pharmaceutical composition of claim 9, wherein the pharmaceutical composition is administered daily at a daily dosage of
18. 10. The method of claim 9, wherein the compound or salt thereof is administered daily in a daily dosage of about 210 mg. A pharmaceutical composition comprising:
19. A therapeutically effective amount of a compound of formula (I) or a pharma- ceutical acceptable salt thereof is administered to a subject in need thereof. A pharmaceutical composition for use in treating cancer in a subject, comprising a cyclic administration schedule. The drug is administered orally for at least one cycle of the schedule, each cycle lasting from about 15 days to and the compound or a salt thereof is administered in an amount of about 80 mg of the compound or a salt thereof. to about 250 mg daily, followed by a drug holiday of about 5 to about 10 days. In the pharmaceutical composition, neither the compound nor its salt is administered. 【Chemistry 2】 (3'R,4'S,5'R)-N-[(3R,6S)-6-carbamoyltetrahydro- 2H-pyran-3-yl]-6"-chloro-4'-(2-chloro-3-fluoropyridine -4-yl)-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclo[(1,2-dihydro- Hexane-1,2'-pyrrolidine-3',3"-indole-5'-carboxamide 。
20. Each cycle has a dosing period of about 15 to about 25 days, and the compound or salt thereof is administered in about 1 00 mg to about 140 mg daily, followed by about 5 to about 10 days of 20. The method according to claim 9, wherein during the drug holiday, neither the compound nor its salt is administered. The pharmaceutical composition according to any one of claims 1 to 4.
21. Each cycle has a dosing period of about 15 to about 25 days, and the compound or salt thereof is administered in about 1 A daily dosage of 20 mg is administered daily, followed by a drug holiday of about 5 to about 10 days.
20. The method according to claim 9, wherein neither the compound nor its salt is administered. Pharmaceutical compositions.
22. Each cycle has a dosing period of about 15 to about 25 days, and the compound or salt thereof is administered in about 1 A daily dosage of 40 mg to about 180 mg is administered daily, followed by about 5 to about 10 days of 20. The method according to claim 9, wherein during the drug holiday, neither the compound nor its salt is administered. The pharmaceutical composition according to any one of claims 1 to 4.
23. Each cycle has a dosing period of about 15 to about 25 days, and the compound or salt thereof is administered in about 1 A daily dosage of 60 mg is administered daily, followed by a drug holiday of about 5 to about 10 days.
20. The method according to claim 9, wherein neither the compound nor its salt is administered. Pharmaceutical compositions.
24. Each cycle has a dosing period of about 15 to about 25 days, and the compound or salt thereof is administered in about 1 A daily dosage of 80 mg to about 250 mg is administered daily, followed by about 5 to about 10 days of 20. The method according to claim 9, wherein during the drug holiday, neither the compound nor its salt is administered. The pharmaceutical composition according to any one of claims 1 to 4.
25. Each cycle has a dosing period of about 15 to about 25 days, and the compound or salt thereof is administered in about 2 A daily dosage of 10 mg is administered daily, followed by a drug holiday of about 5 to about 10 days.
20. The method according to claim 9, wherein neither the compound nor its salt is administered. Pharmaceutical compositions.
26. Each cycle has a dosing period of about 21 days, and the compound or salt thereof is administered in an amount of about 100 mg to about 200 mg. A daily dosage of about 140 mg is administered daily, followed by a drug holiday of about 7 days.
20. The pharmaceutical composition according to claim 9, wherein neither the compound nor a salt thereof is administered. thing.
27. Each cycle has a dosing period of about 21 days, and the compound or salt thereof is administered in an amount of about 140 mg to about 200 mg. A daily dosage of about 180 mg is administered daily, followed by a drug holiday of about 7 days.
20. The pharmaceutical composition according to claim 9, wherein neither the compound nor a salt thereof is administered. thing.
28. Each cycle has a dosing period of about 21 days, and the compound or salt thereof is administered in an amount of about 180 mg to about 200 mg. A daily dosage of about 250 mg is administered daily, followed by a drug holiday of about 7 days.
20. The pharmaceutical composition according to claim 9, wherein neither the compound nor a salt thereof is administered. thing.
29. Each cycle has a dosing period of about 15 to about 25 days, and the compound or salt thereof is administered for about 8 is administered daily at a daily dosage of 0 mg to about 100 mg, preferably about 90 mg, followed by During a drug holiday of about 5 to about 10 days, neither the compound nor its salt is administered.
20. The pharmaceutical composition according to any one of claims 9 to 19.
30. Each cycle has a dosing period of about 15 to about 25 days, and the compound or salt thereof is administered for about 9 0 mg daily, followed by a rest period of about 5 to about 10 days.
20. The pharmaceutical composition according to claim 9, wherein the compound and its salt are not administered. Pharmaceutical composition.
31. Each cycle has a dosing period of about 21 days, and the compound or salt thereof is administered in a dose of about 80 mg to about The compound and 20. The pharmaceutical composition according to any one of claims 9 to 19, wherein neither acetaminophen nor its salts are administered. 。
32. Each cycle has a dosing period of about 21 days, and the compound or a salt thereof is A daily dosage of about 120 mg of the salt is administered daily, followed by a washout period of about 7 days. The pharmaceutical composition according to any one of claims 9 to 19, wherein none of the compounds and their salts is administered. composition.
33. Each cycle has a dosing period of about 21 days, and the compound or a salt thereof is A daily dosage of about 160 mg of the salt is administered daily, followed by a washout period of about 7 days. The pharmaceutical composition according to any one of claims 9 to 19, wherein none of the compounds and their salts is administered. composition.
34. Each cycle has a dosing period of about 21 days, and the compound or a salt thereof is A daily dosage of about 210 mg of the salt is administered daily, followed by a washout period of about 7 days. The pharmaceutical composition according to any one of claims 9 to 19, wherein none of the compounds and their salts is administered. composition.
35. Each cycle has a dosing period of about 21 days, and the compound or a salt thereof is A daily dosage of about 90 mg of the salt is administered daily, followed by a washout period of about 7 days, and salts thereof are not administered. Composition.
36. The method of any one of claims 9 to 35, wherein the cancer is liposarcoma. A pharmaceutical composition for use in treating cancer in a subject.
37. The cancer is a liposarcoma having an amplified MDM2 gene in the liposarcoma genome. The pharmaceutical composition of claim 36 for use in treating cancer in a subject in need thereof. Pharmaceutical composition.
38. The compound or a salt thereof is represented by the formula (II) of p-toluenesulfonate monohydrate.
38. In a subject in need thereof according to any one of claims 1 to 37, A pharmaceutical composition for use in treating cancer. 【Chemistry 3】
39. (3'R,4'S,5'R)-N-[(3R,6S)-6-carbamoyltetrahydro -2H-pyran-3-yl]-6"-chloro-4'-(2-chloro-3-fluoropyridin 4,4-dimethyl-2"-oxo-1",2"-dihydrodispiro[cyano-4-yl] Cyclohexane-1,2'-pyrrolidine-3',3"-indole]-5'-carboxamide A pharmaceutical composition for treating liposarcoma comprising: composition.
40. 40. The method of claim 39, wherein the liposarcoma has an amplified MDM2 gene in the liposarcoma genome. The pharmaceutical composition described above.
